$269 Million is the total value of Tri Locum Partners LP's 59 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNIT | Exit | UNITI GROUP INC | $0 | – | -11,370 | -100.0% | -0.01% | – |
| SWN | Exit | SOUTHWESTERN ENERGY CO | $0 | – | -10,357 | -100.0% | -0.02% | – |
| ETRN | Exit | EQUITRANS MIDSTREAM CORP | $0 | – | -10,131 | -100.0% | -0.02% | – |
| PGRE | Exit | PARAMOUNT GROUP INC | $0 | – | -15,008 | -100.0% | -0.02% | – |
| BTG | Exit | B2GOLD CORP | $0 | – | -19,076 | -100.0% | -0.02% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -160,269 | -100.0% | -0.41% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -528,814 | -100.0% | -0.68% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -106,711 | -100.0% | -0.79% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -28,470 | -100.0% | -0.93% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -107,230 | -100.0% | -1.00% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -1.01% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -88,524 | -100.0% | -1.03% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -17,523 | -100.0% | -1.25% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -227,273 | -100.0% | -1.39% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -77,048 | -100.0% | -1.55% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -255,011 | -100.0% | -1.82% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -76,070 | -100.0% | -2.25% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -49,213 | -100.0% | -2.39% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -268,011 | -100.0% | -2.65% | – |
| TMO | Exit | THERMO FISHER SCIENTIFIC INC | $0 | – | -15,889 | -100.0% | -2.79% | – |
| MRK | Exit | MERCK & CO INC | $0 | – | -114,242 | -100.0% | -3.70% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -88,961 | -100.0% | -3.73% | – |
| ARKK | Exit | ARK ETF TRunit | $0 | – | -350,000 | -100.0% | -4.30% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -417,448 | -100.0% | -5.16% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -174,802 | -100.0% | -5.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 13 | Q2 2024 | 0.5% |
| REGENERON PHARMACEUTICALS | 12 | Q2 2024 | 13.8% |
| XENON PHARMACEUTICALS INC | 11 | Q2 2024 | 4.7% |
| ARGENX SE | 10 | Q2 2024 | 12.8% |
| AVADEL PHARMACEUTICALS PLC | 10 | Q2 2024 | 7.0% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| STEVANATO GROUP S P A | 8 | Q2 2024 | 5.8% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| TEVA PHARMACEUTICAL INDS LTD | 7 | Q2 2024 | 10.8% |
| AXSOME THERAPEUTICS INC | 7 | Q2 2024 | 6.2% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.